bioAffinity Technologies, Inc. - 8-K Filing
bioAffinity Technologies reported Q1 2026 financial results on May 8, 2026, with CyPath® Lung unit sales rising 146% year-over-year and testing revenue increasing to $361,000 (up from $169,000 in the same period of 2025). Total consolidated revenue fell by approximately 27% to $1.4 million due to discontinued unprofitable pathology services. (Items: 2.02 Results of Operation and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $BIAF